{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:36:29Z","timestamp":1761161789361,"version":"build-2065373602"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,21]]},"DOI":"10.7759\/cureus.95077","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:42:48Z","timestamp":1761064968000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Cardiotoxicity in Lymphoproliferative Patients Treated With Anthracycline and Bruton's Tyrosine Kinase Inhibitor-Based Regimens"],"prefix":"10.7759","author":[{"given":"Andrew","family":"Bonsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21349","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller KD","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, et al.. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016, 66:271-89. 10.3322\/caac.21349","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach JA","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, et al.. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018, 379:2517-28. 10.1056\/NEJMoa1812836","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam CS","year":"2020","unstructured":"Tam CS, Opat S, D'Sa S, et al.. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood. 2020, 136:2038-50. 10.1182\/blood.2020006844","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized Phase III trial","volume":"39","author":"Byrd JC","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al.. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized Phase III trial. J Clin Oncol. 2021, 39:3441-52. 10.1200\/JCO.21.01210","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13399","article-title":"Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States","volume":"170","author":"Nabhan C","year":"2015","unstructured":"Nabhan C, Byrtek M, Rai A, et al.. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. Br J Haematol. 2015, 170:85-95. 10.1111\/bjh.13399","journal-title":"Br J Haematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30173","article-title":"Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma","volume":"122","author":"Chihara D","year":"2016","unstructured":"Chihara D, Westin JR, Oki Y, et al.. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016, 122:3145-51. 10.1002\/cncr.30173","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e04-08-0732","article-title":"Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line","volume":"15","author":"Carpenter AJ","year":"2004","unstructured":"Carpenter AJ, Porter AC. Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line. Mol Biol Cell. 2004, 15:5700-11. 10.1091\/mbc.e04-08-0732","journal-title":"Mol Biol Cell"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11101-013-9291-7","article-title":"Phytochemicals as anticancer and chemopreventive topoisomerase II poisons","volume":"13","author":"Ketron AC","year":"2014","unstructured":"Ketron AC, Osheroff N. Phytochemicals as anticancer and chemopreventive topoisomerase II poisons. Phytochem Rev. 2014, 13:19-35. 10.1007\/s11101-013-9291-7","journal-title":"Phytochem Rev"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa Y","year":"2014","unstructured":"Ichikawa Y, Ghanefar M, Bayeva M. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. 2014, 124:617-30.","journal-title":"J Clin Invest"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies","volume":"3","author":"Hahn VS","year":"2014","unstructured":"Hahn VS, Lenihan DJ, Ky B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc. 2014, 3:000665. 10.1161\/JAHA.113.000665","journal-title":"J Am Heart Assoc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd JC","year":"2014","unstructured":"Byrd JC, Brown JR, O'Brien S, et al.. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014, 371:213-23. 10.1056\/NEJMoa1400376","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon SP","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, et al.. Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia. N Engl J Med. 2015, 372:1430-40. 10.1056\/NEJMoa1501548","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt TD","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, et al.. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019, 381:432-43. 10.1056\/NEJMoa1817073","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang S","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012, 18:1639-42. 10.1038\/nm.2919","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir T","year":"2019","unstructured":"Munir T, Brown JR, O'Brien S, et al.. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019, 94:1353-63. 10.1002\/ajh.25638","journal-title":"Am J Hematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated\u00a0with ibrutinib","volume":"74","author":"Salem JE","year":"2019","unstructured":"Salem JE, Manouchehri A, Bretagne M, et al.. Cardiovascular toxicities associated\u00a0with ibrutinib. J Am Coll Cardiol. 2019, 74:1667-78. 10.1016\/j.jacc.2019.07.056","journal-title":"J Am Coll Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00795.2008","article-title":"Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro","volume":"296","author":"Mukhopadhyay P","year":"2009","unstructured":"Mukhopadhyay P, Rajesh M, B\u00e1tkai S, et al.. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol. 2009, 296:1466-83. 10.1152\/ajpheart.00795.2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen JR","year":"2014","unstructured":"McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014, 124:3829-30. 10.1182\/blood-2014-10-604272","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao L","year":"2020","unstructured":"Xiao L, Salem JE, Clauss S, et al.. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation. 2020, 142:2443-55. 10.1161\/CIRCULATIONAHA.120.049210","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen MH","year":"2008","unstructured":"Chen MH, Kerkel\u00e4 R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008, 118:84-95. 10.1161\/CIRCULATIONAHA.108.776831","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035770","article-title":"Anthracyclines and the risk of arrhythmias: a systematic review and meta-analysis","volume":"102","author":"Dean YE","year":"2023","unstructured":"Dean YE, Dahshan H, Motawea KR, et al.. Anthracyclines and the risk of arrhythmias: a systematic review and meta-analysis. Medicine (Baltimore). 2023, 102:35770. 10.1097\/MD.0000000000035770","journal-title":"Medicine (Baltimore)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2016.07.049","article-title":"Prognostic significance of new-onset atrial fibrillation in patients with non-Hodgkin\u2019s lymphoma treated with anthracyclines","volume":"118","author":"Amioka M","year":"2016","unstructured":"Amioka M, Sairaku A, Ochi T, Okada T, Asaoku H, Kyo T, Kihara Y. Prognostic significance of new-onset atrial fibrillation in patients with non-Hodgkin\u2019s lymphoma treated with anthracyclines. Am J Cardiol. 2016, 118:1386-9. 10.1016\/j.amjcard.2016.07.049","journal-title":"Am J Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000529260","article-title":"Off-target effects of cancer therapy on development of therapy-induced arrhythmia: a review","volume":"148","author":"Leiva O","year":"2023","unstructured":"Leiva O, Bohart I, Ahuja T, Park D. Off-target effects of cancer therapy on development of therapy-induced arrhythmia: a review. Cardiology. 2023, 148:324-34. 10.1159\/000529260","journal-title":"Cardiology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon AR","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al.. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022, 43:4229-361. 10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.06.005","article-title":"Cardiovascular considerations during cancer therapy: gaps in evidence and JACC: CardioOncology expert panel recommendations","volume":"6","author":"Leong DP","year":"2024","unstructured":"Leong DP, Waliany S, Abdel-Qadir H, et al.. Cardiovascular considerations during cancer therapy: gaps in evidence and JACC: CardioOncology expert panel recommendations. JACC CardioOncol. 2024, 6:815-34. 10.1016\/j.jaccao.2024.06.005","journal-title":"JACC CardioOncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/356987-evaluation-of-cardiotoxicity-in-lymphoproliferative-patients-treated-with-anthracycline-and-brutons-tyrosine-kinase-inhibitor-based-regimens","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:42:48Z","timestamp":1761064968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/356987-evaluation-of-cardiotoxicity-in-lymphoproliferative-patients-treated-with-anthracycline-and-brutons-tyrosine-kinase-inhibitor-based-regimens"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.95077","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,10,21]]}}}